EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

A de novo deletion underlying spinal muscular atrophy: implications for carrier testing and genetic counseling

Maria M Zwartkruis iD, Mirjam S de Pagter, Demi Gommers iD, Marije Koopmans, Cecile P E Ottenheim, Joris V Kortooms, Mirjan Albring, Martin G Elferink, Renske I Wadman, Fay-Lynn Asselman, Inge Cuppen, W Ludo van der Pol und 3 weitere

Human Molecular Genetics · 06.05.2025 · 34 (10) · 894-904

DOI: 10.1093/hmg/ddaf035 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Human Molecular Genetics, online erschienen am 17.03.2025. Verfasst von Maria M Zwartkruis und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Nethe…. Hauptthemen laut MEDLINE: Genetic Carrier Screening, Muscular Atrophy, Spinal, Sequence Deletion, Survival of Motor Neuron 1 Protein. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stichting Spieren voor Spieren, European Union's Horizon 2020 Research and Innovation Program, Marie Skłodowska-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spinal muscular atrophy (SMA) is an autosomal recessive disease most commonly caused by homozygous deletion of the SMN1 gene. Parents of affected children are typically carriers, with a recurrence risk of 25% for future pregnancies. Their close relatives have up to 50% chance of being carriers. Carriers typically possess a single copy of the SMN1 gene; however, some parents carry two copies of SMN1. Current standard diagnostic carrier tests are unable to distinguish between silent carriers with two copies on one chromosome (2 + 0 genotype) and non-carriers (1 + 1 genotype), where a de novo deletion occurred. This distinction is crucial for recurrence risk assessment, which highlights the unsolved challenge to carrier testing and genetic counseling. We combined microsatellite marker analysis, SMN copy number analysis, Sanger sequencing, long-read sequencing and de novo assembly to investigate the cause of the absence of SMN1 in a pedigree with an SMA patient identified through newborn screening, whose parents each carried two SMN1 copies. Our analysis revealed that the father is a silent carrier, while de novo assembly of the SMN locus showed a 1.4 megabase (Mb) de novo deletion between mother and child. This deletion encompasses SMN1 and SMN2 and represents the first reported nucleotide-level resolved SMA-causing deletion to date. Our findings allowed informed counseling of at-risk relatives and illustrate the complexity of SMA carrier testing and counseling. This case underscores the feasibility of and need for advanced genetic testing for SMA carriership in select cases, to improve genetic counseling practices, risk assessment, and family planning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic Carrier ScreeningMuscular Atrophy, SpinalSequence DeletionSurvival of Motor Neuron 1 ProteinFemaleHumansInfant, NewbornGene DeletionGenetic CounselingGenetic TestingHeterozygotePedigree

Stichwörter der Autor:innen

carrier screeningclinical geneticslong-read sequencingspinal muscular atrophysurvival motor neuron

Substanzen

SMN1 protein, humanSurvival of Motor Neuron 1 Protein

Autor:innen und Institutionen

  • Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands.
  • Department of Genetics, University Medical Center Utrecht, Heidelberglaan 100, Utrecht 3584 CX, the Netherlands.
  • Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands.

ORCID-Profile: Maria M Zwartkruis, Demi Gommers, Ewout J N Groen

Förderung

  • Stichting Spieren voor Spieren
  • European Union's Horizon 2020 Research and Innovation Program
  • Marie Skłodowska-Curie Actions
  • Prinses Beatrix Spierfonds
  • European Union’s Horizon 2020 Research and Innovation Program

Zitieren

APA

Zwartkruis, M. M., de Pagter, M. S., Gommers, D., Koopmans, M., Ottenheim, C. P. E., Kortooms, J. V., Albring, M., Elferink, M. G., Wadman, R. I., Asselman, F. L., Cuppen, I., van der Pol, W. L., Nelen, M. R., van Haaften, G. W., & Groen, E. J. N. (2025). A de novo deletion underlying spinal muscular atrophy: implications for carrier testing and genetic counseling. Human Molecular Genetics, 34(10), 894-904. https://doi.org/10.1093/hmg/ddaf035

Vancouver

Zwartkruis MM, de Pagter MS, Gommers D, Koopmans M, Ottenheim CPE, Kortooms JV, et al. A de novo deletion underlying spinal muscular atrophy: implications for carrier testing and genetic counseling. Human Molecular Genetics. 2025;34(10):894-904. doi:10.1093/hmg/ddaf035

BibTeX
@article{Zwartkruis2025,
  author = {Zwartkruis, Maria M and de Pagter, Mirjam S and Gommers, Demi and Koopmans, Marije and Ottenheim, Cecile P E and Kortooms, Joris V and Albring, Mirjan and Elferink, Martin G and Wadman, Renske I and Asselman, Fay-Lynn and Cuppen, Inge and van der Pol, W Ludo and Nelen, Marcel R and van Haaften, Gijs W and Groen, Ewout J N},
  title = {A de novo deletion underlying spinal muscular atrophy: implications for carrier testing and genetic counseling},
  journal = {Human Molecular Genetics},
  year = {2025},
  volume = {34},
  number = {10},
  pages = {894--904},
  doi = {10.1093/hmg/ddaf035}
}
Kostenlos starten →